CMV reactivation post-allogeneic stem cell transplantation decreases relapse risk in patients with myeloid malignancy, but decreases survival and increases non-relapse mortality.
Does CMV reactivation post allogeneic stem cell transplantation affect relapse risk, survival, and non-relapse mortality?
CMV reactivation post allogeneic stem cell transplantation is associated with decreased relapse risk in myeloid malignancy, but refractory CMV increases CMV-related mortality.
Absolute Event Rate: 0% vs 0%
= 0.13 vs. refractory). CMV reactivation was associated with lower relapse risk in patients with myeloid malignancy, although the biological basis of this association remains uncertain. Refractory CMV increases CMV-related mortality, but probable refractory CMV does not increase mortality risk.
Stavi et al. (Thu,) reported a other. CMV reactivation post-allogeneic stem cell transplantation decreases relapse risk in patients with myeloid malignancy, but decreases survival and increases non-relapse mortality.